[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354306-105":59,"doc-detail-354306-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","limited-clinical-benefit-of-immune-checkpoint-inhibition-in-ovarian-cancer-with-opportunities-in-selected-subtypes-article","Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes - Article","","Epithelial ovarian cancer remains one of the most lethal gynecologic malignancies, driven by late-stage diagnosis, relapse, and eventual therapeutic resistance. Although immune checkpoint inhibitors have transformed outcomes in several solid tumors, their clinical impact in ovarian cancer has been comparatively limited. This review synthesizes recent advances in ICI strategies, focusing on phase II–III trials of PD-1/PD-L1, CTLA-4, and TIM-3–directed therapies. Evidence suggests modest activity for PD-1/PD-L1 monotherapy, improved antitumor effects with PD-1 plus CTLA-4 in selected subtypes, and limited benefit in biomarker-unselected settings, while combination regimens show promise in molecularly defined groups.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/limited-clinical-benefit-of-immune-checkpoint-inhibition-in-ovarian-cancer-with-opportunities-in-selected-subtypes-article/354306/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/limited-clinical-benefit-of-immune-checkpoint-inhibition-in-ovarian-cancer-with-opportunities-in-selected-subtypes-article/354306.png","ImageObject",300,407,{"name":92,"@type":93},"Mimi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why has ovarian cancer been difficult to treat with immune checkpoint inhibitors?","Question",{"text":112,"@type":113},"Clinical impact has been comparatively modest due to advanced-stage presentation, high relapse rates, and the emergence of therapeutic resistance, with evidence showing limited activity in biomarker-unselected populations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What do phase II–III trials suggest about PD-1/PD-L1 therapy in ovarian cancer?",{"text":117,"@type":113},"Accumulating evidence indicates low objective response rates and minimal survival benefit for PD-1/PD-L1 monotherapy in unselected ovarian cancer populations.",{"name":119,"@type":110,"acceptedAnswer":120},"How does dual checkpoint blockade (PD-1 plus CTLA-4) compare with monotherapy?",{"text":121,"@type":113},"Dual blockade shows enhanced antitumor activity, particularly in clear cell ovarian carcinoma, but it comes with increased immune-related toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354306,1790240081,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nLimited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes  \nZuzanna Ratka 1, Andrzej Gamian 2 and Marta Wo´zniak 1, *  \nAcademic Editor: Alfonso Baldi  \nReceived: 20 April 2026  \nRevised: 10 May 2026  \nAccepted: 18 May 2026  \nPublished: 29 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Clinical and Experimental Pathology, Wroclaw Medical University, Marcinkowskiego 1, 50-368 Wroclaw, Poland; [zuzanna.ratka@student.umw.edu.pl](zuzanna.ratka@student.umw.edu.pl)  \n2 Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 Rudolfa Weigla Str., 53-114 Wroclaw, Poland  \n* [Correspondence: marta.wozniak@umw.edu.pl](Correspondence: marta.wozniak@umw.edu.pl)  \nAbstract  \nEpithelial ovarian cancer (EOC) remains one of the most lethal gynecologic malignancies, largely owing to advanced-stage presentation, high rates of relapse, and the eventual emergence of therapeutic resistance. Despite the transformative success of immune checkpoint inhibitors (ICIs) across multiple solid tumors, their clinical impact in ovarian cancer has been comparatively modest. This literature review provides a comprehensive synthesis of recent advances in ICI strategies for ovarian cancer (OC), with particular emphasis on phase II and III clinical trials evaluating programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), and T cell immunoglobulin and mucin-domain-containing-3 (TIM-3)-directed therapies. Accumulating evidence indicates that PD-1/PD-L1 monotherapy yields limited clinical activity in unselected OC populations, with low objective response rates and minimal survival benefit. Dual checkpoint blockade with PD-1 and CTLA-4 inhibitors demonstrates enhanced antitumor activity, particularly in clear cell ovarian carcinoma (CCOC), albeit atthe expense of increased immune-related toxicity. Large randomized trials incorporating ICI into first-line chemotherapy or maintenance settings have largely failed to improve outcomes in biomarker-unselected cohorts. Available evidence demonstrates that combinatorial approaches integrating ICI with anti-angiogenic agents, PARP inhibitors, or neoadjuvant chemotherapy provide modest benefit in selected molecular and histologic subgroups. Early-phase investigations of TIM-3–targeting strategies further expand the immunotherapeutic landscape, although clinical efficacy remains preliminary. Current evidence underscores that OC is not uniformly responsive to immunotherapy and that rational combination strategies, biomarker-driven patient selection, and improved understanding of tumor immune microenvironment heterogeneity are essential to unlocking the full therapeutic potential of ICI in this disease.  \nKeywords: ovarian cancer; immune checkpoint inhibitors; immunotherapy; PD-1/PD-L1; CTLA-4; TIM-3; clear cell ovarian carcinoma; clinical trials  \n1. Introduction  \nOC remains one of the most formidable and challenging entities in contemporary gynecologic oncology, distinguished by persistently high mortality rates and an insidious, frequently asymptomatic course during its initial phases of progression. According to GLOBOCAN 2022 estimates, more than 324,000 new cases and nearly 207,000 deaths  \nwere recorded worldwide, positioning OC as one of the leading causes of cancer-related mortality among women globally [1] . The median age at diagnosis is approximately 63 years, and the disease manifests far more frequently in older women than in younger cohorts. Moreover, both the incidence and mortality associated with OC are notably higher in developed regions compared with developing nations [2] . The stage at diagnosis of OC varies widely. High-grade serous carcinomas (HGSCs) are","cbCaipypUot5AaoD","https://ap.wps.com/l/cbCaipypUot5AaoD","pdf",1736521,26,"English","# Introduction\n## Background and clinical burden\n## Risk factors and epidemiology\n## Molecular and histologic heterogeneity\n## Rationale for immune checkpoint inhibition","[{\"question\":\"Why has ovarian cancer been difficult to treat with immune checkpoint inhibitors?\",\"answer\":\"Clinical impact has been comparatively modest due to advanced-stage presentation, high relapse rates, and the emergence of therapeutic resistance, with evidence showing limited activity in biomarker-unselected populations.\"},{\"question\":\"What do phase II–III trials suggest about PD-1/PD-L1 therapy in ovarian cancer?\",\"answer\":\"Accumulating evidence indicates low objective response rates and minimal survival benefit for PD-1/PD-L1 monotherapy in unselected ovarian cancer populations.\"},{\"question\":\"How does dual checkpoint blockade (PD-1 plus CTLA-4) compare with monotherapy?\",\"answer\":\"Dual blockade shows enhanced antitumor activity, particularly in clear cell ovarian carcinoma, but it comes with increased immune-related toxicity.\"}]","Limited Clinical Benefit of Immune Checkpoint Inhibition in Ovarian Cancer with Opportunities in Selected Subtypes - Article | PDF",1790109976,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d7f7f0db3c010dc5bc7d4040061649a.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e623ab5e4b86437d8cf89a8a58a9eb1f.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66408d8c6aa48dd9024f7a435ecbd693.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f50f84abfd837422279d08200648466.webp",980,1385]